RadioBDC Logo
Aberdeen | Cage The Elephant Listen Live
THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Vertex seeks OK for 2d new drug in a year

By Robert Weisman
Globe Staff / October 20, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Five months after it won regulatory approval for its first drug, a treatment for the hepatitis C virus, Vertex Pharmaceuticals Inc. yesterday said it has filed its second new drug application to the Food and Drug Administration in the past year. T he latest Vertex drug candidate, Kalydeco, targets the defective protein that causes cystic fibrosis. If approved, it could help propel the Cambridge biotechnology firm toward its goal of becoming a drug maker with multiple products.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.